Neuland Labs fiscal 2011 revenues increase 41% to $88.8 million

Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the 2011 fiscal year (FY) ended March 31, 2011.

"I am pleased to report that in fiscal year 2011, Neuland delivered on our commitment to return the company to profitability and robust growth," said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs.  "We achieved increases in revenues across all of our lines of business, with especially strong gains in Active Pharmaceutical Ingredients sales.  We significantly increased our operating cash flow by almost doubling EBITDA from last year, and also posted a modest profit.  We are optimistic that the strategic and operational initiatives that helped produce these encouraging results will enable us to achieve continued sales and profit growth in the current year."

Revenues for FY 2011 were $88.8 million (3.99 billion INR) compared to FY 2010 revenues of $62.9 million (2.83 billion INR), an increase of 41%.  The increase in revenues primarily reflects gains in sales of the company's products and services from its API, Contract Research and Manufacturing, and Peptides businesses.

Neuland reported FY 2011 EBITDA of $11.1 million (500 million INR), compared to EBITDA of $6.2 million (281 million INR) in FY 2010, an increase of 78%.  The increase in EBITDA reflected higher sales revenues and improved capacity utilization, as well as the company's success in reducing its debt obligations during the 2011 fiscal year.

After-tax profits in FY 2011 were $1.1 million (51 million INR), compared to a net loss of $1.5 million (70 million INR) in FY 2010.

"The across-the-board gains we achieved in FY 2011 show that we are beginning to reap the benefits of the investments we made over the past few years," commented Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs. "We also made good progress in reducing the debt we had incurred to help finance those investments, and we look forward to further gains as well in our ongoing enterprise-wide efforts to strengthen our margins."